ALVO Company Profile and Key Details

Q: Who are the executives of ALVO?

Mr. Robert WessmanFounder & Executive Chairman of DirectorsMr. Mark LevickChief Executive OfficerMs. Sigridur Elin GudlaugsdottirVice President of HRMr. Joel MoralesChief Financial OfficerDr. Hafrun Fridriksdottir Ph.D.Chief Operating OfficerMr. Giedrius ZundaChief Technical OfficerMr. Joseph E. McClellanChief Scientific OfficerMs. Tanya ZharovGen. CounselMr. Sean GaskellChief Technical OfficerMs. Rose-Marie OhlssonChief Information OfficerMr. Anil OkayChief Commercial OfficerMs. Eva Yr GunnlaugsdottirVice President of People & Culture

NASDAQ : ALVO

Alvotech

$3.65

0.03+0.83%

At Close 4:00 PM

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Alvotech (ALVO) stock surged +0.83%, trading at $3.65 on NASDAQ, up from the previous close of $3.62. The stock opened at $3.53, fluctuating between $3.49 and $3.67 in the recent session.

Stock Snapshot

3.62

Prev. Close

1.14B

Market Cap

3.49

Day Low

36.5

P/E Ratio

0.1

EPS (TTM)

-1.34

Cash Flow per Share

3.53

Open

311.6M

Number of Shares

3.665

Day High

37.57%

Free Float in %

-3.49

Book Value

244.92K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	3.55	3.67	3.49	3.65	246.83K
Apr 01, 2026	3.55	3.69	3.55	3.62	473.33K
Mar 31, 2026	3.33	3.47	3.27	3.43	605.03K
Mar 30, 2026	3.13	3.35	3.10	3.29	722.54K
Mar 27, 2026	3.23	3.24	3.10	3.11	317.84K
Mar 25, 2026	3.21	3.29	3.13	3.14	346.68K
Mar 24, 2026	3.28	3.28	3.03	3.13	1.13M
Mar 23, 2026	3.54	3.54	3.31	3.33	877.71K
Mar 20, 2026	3.57	3.62	3.44	3.53	1.26M
Mar 19, 2026	3.66	3.68	3.42	3.58	977.51K
Mar 18, 2026	3.79	3.85	3.70	3.80	638.23K
Mar 17, 2026	3.66	3.88	3.66	3.82	391.87K
Mar 16, 2026	3.53	3.65	3.51	3.61	481.63K
Mar 13, 2026	3.58	3.63	3.45	3.47	548.79K
Mar 12, 2026	3.73	3.78	3.53	3.54	1.2M
Mar 11, 2026	3.86	3.90	3.70	3.73	638.73K
Mar 10, 2026	4.03	4.08	3.82	3.88	368.67K
Mar 09, 2026	3.95	4.03	3.80	4.02	370.95K
Mar 06, 2026	4.10	4.11	3.99	4.01	311.5K
Mar 03, 2026	3.85	3.88	3.65	3.80	935.41K

Contact Details

Luxembourg, 102

Iceland

https://www.alvotech.com 354 422 4500

About Company

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Stock Peers

ITCI

Intra-Cellular Therapies, Inc.$131.87 NBIX

-0.96-0.72%

Neurocrine Biosciences, Inc.$131.60 LNTH

0.4+0.53%

Lantheus Holdings, Inc.$76.10 ANIP

-1.75-2.30%

ANI Pharmaceuticals, Inc.$74.21 PAHC

0.76+1.39%

Phibro Animal Health Corporation$55.52 SUPN

-0.96-1.87%

Supernus Pharmaceuticals, Inc.$50.48 HROW

-0.12-0.34%

Harrow Health, Inc.$35.31 COLL

-0.94-2.83%

Collegium Pharmaceutical, Inc.$32.31 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98 RGC

-2.92-8.66%

Regencell Bioscience Holdings Limited$30.80

Company Overview

Alvotech (NASDAQ:ALVO) closed at $3.65 USD, gaining $0.03 (0.83%) from the previous close of $3.62. The stock is currently mid-range between its 52-week high and low $3.03 and $11.85. With a market capitalization of about $1.14 billion, Alvotech is classified as a small-cap and shows lower-than-market volatility (beta ~0.25). Key stats such as the average daily volume over the past year has been around 541.54 thousand shares, volume is running light vs its 52-week average. Headquartered in Luxembourg, None, Alvotech operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Vilhelm Robert Wessman, the company employs approximately 1,012 people and listed since June 16, 2022. Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.

Technical Performance

ALVO has shown mixed momentum, gaining 0.61% over the past week and -43.12% over the past quarter, though year-to-date performance is down -3.31%. Short-term trend indicators are bullishly aligned (SMA20 -12.52%, SMA50 -15.15%, SMA200 -43.76%). The stock’s 14-day RSI is 30.62 (weak momentum), while the ATR of 0.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -65.01% below its high and over 5.85% above its low. Average 10-day trading volume of 452.04 thousand shares is below the 3-month average of 534.69 thousand, indicating normal recent market interest.

Valuation Metrics

Alvotech trades at a P/E ratio of 36.5, slightly above the S&P 500 average, with a price-to-sales ratio of 1.94 and a price-to-book ratio of -3.58 indicating negative book value, which may reflect financial stress. The P/FCF stands at -9.92, also above market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Alvotech generated EPS of $0.23 over the past year. Five-year average earnings growth is -30.68%. The latest quarter delivered EPS of -$0.02. The next quarter is forecast at $0.00. Next year's EPS is expected at $67.57. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $14.00 to $4.00. The high target offers 283.56% upside. The low target suggests 9.59% downside. The mean target is $10.92. This offers 199.18% upside. Alvotech earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -140.0%. The prior quarter beat by -153.85%. Over the last six quarters, Apple has recorded several small beats. These include -200.0% in August 15, 2024.

Shareholding & Insider Activity

Alvotech has 311.60 million shares outstanding. The public float is 114.08 million shares, elevated short interest at 2.07% of float. This equals 2.46 million shares. The short ratio is 3.52 days. Institutional investors hold 15.3% of the float. Insiders own 61.77%.

Financial & Profitability Overview

Over the trailing twelve months, Alvotech generated $91.43M in revenue, or $0.40 per share. Gross margin was -75.93%, operating margin -388.11%, and net profit margin -603.42%. Returns are negative, with ROA at -58.07% and ROE at 59.17%.
On valuation metrics, Alvotech trades at a P/E of 36.50, P/S of 1.94 and P/B of -3.58. The current ratio is 1.89 and quick ratio is 1.16. Operationally, the company’s inventory turnover is 1.07 and cash conversion cycle is 188.96 days. Debt-to-equity is -5.09, supported by a cash flow-to-debt ratio of -0.03.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Alvotech posted revenue of $91.43M, down slightly from $83.03M in the prior quarter. Gross profit was - $69.42M (margin -75.93%). Operating income was - $354.86M (margin -388.1%). Net income was- $551.73M (EPS - $2.43).
The company ended the quarter with $11.16M in cash and short-term investments, a total debt of $1.08B, and net debt of $1.06B. Total assets were $950.09M, with equity of - $932.49M. Financials further reflected weakness, with operating cash flow of - $312.19M, free cash flow of - $358.66M, and capital expenditures of - $46.47M.

Price Forecast & Outlook

Our AI price prediction model suggests that Alvotech stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.33%, with price expected at $3.20 by April 16, 2026, within a range of $3.03 to $3.39 3-Month Outlook: Projected fall of -25.75%, reaching $2.71 by July 01, 2026, with a range of $2.48 to $2.93. 1-Year Outlook: Projected loss of -85.48%, with price at $0.53 by April 02, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Alvotech (NASDAQ:ALVO) shares are flat -3.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Alvotech trading at a premium to the broader market with a P/E of 36.5. Analyst sentiment is cautious, with the majority of ratings in Underweight territory and a mean price target of $11.52, suggesting 215.62% upside. Our AI forecast model points to short-term weakness (-12.33% over two weeks), a medium-term fall (-25.75% over three months), and a longer-term loss (-85.48% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Alvotech (ALVO) stock price?

Alvotech (NASDAQ: ALVO) stock price is $3.65 in the last trading session. During the trading session, ALVO stock reached the peak price of $3.67 while $3.49 was the lowest point it dropped to. The percentage change in ALVO stock occurred in the recent session was 0.83% while the dollar amount for the price change in ALVO stock was $0.03.

ALVO's industry and sector of operation?

The NASDAQ listed ALVO is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Alvotech designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ALVO?

Mr. Robert Wessman
Founder & Executive Chairman of Directors
Mr. Mark Levick
Chief Executive Officer
Ms. Sigridur Elin Gudlaugsdottir
Vice President of HR
Mr. Joel Morales
Chief Financial Officer
Dr. Hafrun Fridriksdottir Ph.D.
Chief Operating Officer
Mr. Giedrius Zunda
Chief Technical Officer
Mr. Joseph E. McClellan
Chief Scientific Officer
Ms. Tanya Zharov
Gen. Counsel
Mr. Sean Gaskell
Chief Technical Officer
Ms. Rose-Marie Ohlsson
Chief Information Officer
Mr. Anil Okay
Chief Commercial Officer
Ms. Eva Yr Gunnlaugsdottir
Vice President of People & Culture

How ALVO did perform over past 52-week?

ALVO's closing price is 20.46% higher than its 52-week low of $3.03 where as its distance from 52-week high of $11.85 is -69.2%.

How many employees does ALVO have?

Number of ALVO employees currently stands at 1,012.

Link for ALVO official website?

Official Website of ALVO is: https://www.alvotech.com

How do I contact ALVO?

ALVO could be contacted at phone 354 422 4500 and can also be accessed through its website. ALVO operates from Saemundargata 15-19, Luxembourg, 102, Iceland.

How many shares of ALVO are traded daily?

ALVO stock volume for the day was 244.92K shares. The average number of ALVO shares traded daily for last 3 months was 541.55K.

What is the market cap of ALVO currently?

The market value of ALVO currently stands at $1.14B with its latest stock price at $3.65 and 311.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1012
Beta	0.25
Sales or Revenue	$91.43M
5Y Sales Change%	2.071%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

ALVO Company Profile and Key Details

Alvotech

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Price Forecast & Outlook

Key Takeaways